THC Farmaceuticals(CBDG)
$0.020.00 (0.00%)
CBDG
THC Farmaceuticals financials statements
$0.02
At close:0.00 (0.00%)
THC Farmaceuticals (CBDG) Ratios
22 Followers
THC Farmaceuticals Ratios
CBDG's free cash flow for Q3 2022 was $-4.48K. For the 2022 fiscal year, CBDG's free cash flow was increased by $0.00 and operating cash flow was $-4.48K. See a summary of the company’s cash flow.
| Ratios | Sep 23 | Sep 22 | Sep 21 | Sep 20 | Sep 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.12 | 4.67 | 1.15 | 1.19 | 0.60 |
| Quick Ratio | 0.12 | 4.67 | 1.15 | 1.19 | 0.60 |
| Cash Ratio | 0.01 | 0.01 | 0.03 | 0.00 | 0.00 |
| Solvency Ratio | -0.07 | 3.03 | -0.01 | -0.11 | -0.46 |
| Operating Cash Flow Ratio | 4.47 | 2.24 | -0.02 | -0.00 | -0.12 |
| Short-Term Operating Cash Flow Coverage | 4.49 | 2.25 | -0.03 | -0.01 | -0.15 |
| Net Current Asset Value | $ -125.68K | $ 520.83K | $ 90.97K | $ 106.82K | $ -436.43K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.05 | 0.13 | 0.15 | 0.36 |
| Debt-to-Equity Ratio | 0.04 | 0.04 | 0.13 | 0.15 | 0.47 |
| Debt-to-Capital Ratio | 0.04 | 0.04 | 0.12 | 0.13 | 0.32 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 0.86 | 0.86 | 1.00 | 0.99 | 1.29 |
| Debt Service Coverage Ratio | -0.18 | 3.04 | -0.04 | -0.35 | -1.08 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.78 | 0.04 | 0.41 | 0.21 | 0.18 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.02 | 0.02 | 0.06 |
| Net Debt to EBITDA | -5.59 | 0.33 | -22.32 | -2.84 | -0.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 61.92% | 57.39% | 100.00% | 74.16% |
| EBIT Margin | 0.00% | 4260.61% | -752.28% | -1592.73% | -9762.99% |
| EBITDA Margin | 0.00% | 4298.69% | -709.67% | -1580.16% | -9753.64% |
| Operating Profit Margin | 0.00% | -84.91% | -797.22% | -431.68% | -1550.97% |
| Pretax Profit Margin | 0.00% | 4260.61% | -752.28% | -1592.73% | -9762.99% |
| Net Profit Margin | 0.00% | 4269.05% | -376.90% | -797.95% | -4891.26% |
| Continuous Operations Profit Margin | 0.00% | 4260.61% | -752.28% | -1592.73% | -9762.99% |
| Net Income Per EBT | 50.00% | 100.20% | 50.10% | 50.10% | 50.10% |
| EBT Per EBIT | 100.00% | -5017.80% | 94.36% | 368.96% | 629.48% |
| Return on Assets (ROA) | -0.55% | 15.38% | -0.30% | -2.60% | -19.69% |
| Return on Equity (ROE) | -0.47% | 13.28% | -0.30% | -2.58% | -25.47% |
| Return on Capital Employed (ROCE) | -1.15% | -0.32% | -0.81% | -1.84% | -10.94% |
| Return on Invested Capital (ROIC) | -1.09% | -0.31% | -0.69% | -1.54% | -6.69% |
| Return on Tangible Assets | -1.35% | 37.59% | -0.47% | -19.92% | -168.04% |
| Earnings Yield | -8.26% | 11.83% | -0.93% | -3.71% | -9.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.02 | 0.00 | 0.01 | 0.02 |
| Payables Turnover | 0.00 | 0.00 | 0.03 | 0.00 | 0.24 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.44 | 0.35 | 1.02 | 1.22 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.03 | 0.02 | -0.05 | 0.09 |
| Cash Conversion Cycle | 0.00 | 23221.85 | 92202.17 | 30386.74 | 20809.22 |
| Days of Sales Outstanding | 0.00 | 23221.85 | 103714.24 | 30386.74 | 22307.33 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 11512.07 | 0.00 | 1498.11 |
| Operating Cycle | 0.00 | 23221.85 | 103714.24 | 30386.74 | 22307.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.04 | 0.02 | -0.00 | -0.00 | -0.01 |
| Free Cash Flow Per Share | 0.04 | 0.02 | -0.00 | -0.00 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 211845.67 | 63577.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 211845.67 | 63577.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 4.49 | 2.25 | -0.03 | -0.01 | -0.15 |
| Operating Cash Flow to Sales Ratio | 0.00 | 31.79 | -5.26 | -0.29 | -13.17 |
| Free Cash Flow Yield | 350.52% | 8.81% | -1.29% | -0.14% | -2.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.11 | 8.45 | -107.89 | -26.94 | -10.34 |
| Price-to-Sales (P/S) Ratio | 0.00 | 360.82 | 406.62 | 214.95 | 505.82 |
| Price-to-Book (P/B) Ratio | 0.06 | 1.12 | 0.33 | 0.69 | 2.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.29 | 11.35 | -77.24 | -738.09 | -38.41 |
| Price-to-Operating Cash Flow Ratio | 0.29 | 11.35 | -77.24 | -738.09 | -38.41 |
| Price-to-Earnings Growth (PEG) Ratio | 0.12 | -0.00 | 1.25 | 0.31 | -0.00 |
| Enterprise Value Multiple | -12.84 | 8.72 | -79.61 | -16.44 | -6.11 |
| Enterprise Value | 321.12K | 3.75M | 1.26M | 1.97M | 6.07M |
| EV to EBITDA | -12.84 | 8.72 | -79.61 | -16.44 | -6.11 |
| EV to Sales | 0.00 | 374.80 | 565.00 | 259.85 | 595.50 |
| EV to Free Cash Flow | 0.51 | 11.79 | -107.33 | -892.28 | -45.22 |
| EV to Operating Cash Flow | 0.51 | 11.79 | -107.32 | -892.28 | -45.22 |
| Tangible Book Value Per Share | 0.05 | 0.05 | 0.07 | -0.01 | -0.05 |
| Shareholders’ Equity Per Share | 0.18 | 0.18 | 0.15 | 0.14 | 0.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | 0.02 | -0.00 | -0.00 | -0.03 |
| Tax Burden | 0.50 | 1.00 | 0.50 | 0.50 | 0.50 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 1.47 | 8.54 | 5.19 | 16.25 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -42.44 | 0.74 | 1.40 | 0.04 | 0.27 |
Currency in USD
